Navigation Links
Sorin And Cyberonics Announce Intent To Vigorously Contest Claim By Italian State's Attorney Seeking To Enjoin The Proposed Combination Of The Companies

MILAN and HOUSTON, July 27, 2015 /PRNewswire/ -- Sorin S.p.A., (MTA; Reuters Code: SORN.MI "Sorin"), a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc. (NASDAQ: CYBX, "Cyberonics"), a medical device company with core expertise in neuromodulation, today announced Sorin's intent to vigorously contest a claim by the state's attorney of Milan (Avvocato dello Stato di Milano or the "Italian State's Attorney") seeking to enjoin the previously announced combination of Sorin and Cyberonics. The claim (made pursuant to Article 2503, IIc. of the Italian Civil Code) was filed with the Civil Court of Milan on behalf of the Italian Ministry of the Environment and other Italian public authorities, and received by Sorin on July 24th, 2015.

Sorin and Cyberonics announced on February 26, 2015 that the boards of directors of both companies unanimously approved a combination of the companies (the "Transaction") under a newly formed holding company, LivaNova PLC, previously Sand HoldCo PLC ("LivaNova" or "HoldCo").  LivaNova is organized under the laws of England and Wales.  The Transaction, which remains subject to approval by Cyberonics shareholders, was overwhelmingly approved by Sorin shareholders on May 26, 2015.

The Italian State's Attorney alleges in the claim that the Transaction is intended to insulate Sorin from potential liability related to pending environmental litigation against Sorin's previous parent, SNIA S.p.A.. After reviewing the allegation, Sorin and Cyberonics believe the Italian State's Attorney fundamentally misunderstands and misconstrues the structure and goals of the Transaction, as well as Italian and European laws and regulations governing these types of transactions. Sorin and Cyberonics believe that the allegations by the Italian State's Attorney are without merit, and Sorin intends to contest them in the Civil Court of Milan.

"We will vigorously contest this claim and seek expedited hearings for this purpose. In the meantime, our two companies' integration plans are progressing well and will continue. At this point, the effect of the Italian State's Attorney's claim on the timing of the closing of the Transaction is unclear, however we will continue to progress towards our scheduled closing and keep both external and internal stakeholders informed of developments," said André-Michel Ballester, Sorin's Chief Executive Officer and designated Chief Executive Officer of LivaNova. 

The Transaction will create a new premier global medical technology company. LivaNova will have a strategic presence in over 100 countries on five continents around the world, with approximately 4,500 employees.

About Sorin Group
Sorin ( is a global, medical device company and a leader in the treatment of cardiovascular diseases.  Sorin develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With approximately 3,900 employees worldwide, Sorin focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin devices in more than 100 countries.

About Cyberonics
Cyberonics ( is a medical device company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy® System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy system in selected markets worldwide. Cyberonics also has CE Mark for the VITARIA™ System, providing  autonomic regulation therapy for chronic heart failure.

Important Information for Investors This press release is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the United States Securities Act of 1933, as amended (the "Securities Act"), and applicable European regulations. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. This communication does not represent an investment solicitation in Italy, pursuant to Section 1, letter (t) of Legislative Decree no. 58 of February 24, 1998, as amended.

LivaNova plc ("HoldCo") has filed with the United States Securities and Exchange Commission (the "SEC") a registration statement on Form S-4, which includes a preliminary proxy statement of Cyberonics, Inc. ("Cyberonics") that also constitutes a preliminary prospectus of HoldCo (the "proxy statement/prospectus"). A definitive proxy statement/prospectus will be delivered as required by applicable law after the registration statement on Form S-4 is declared effective by the SEC. INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SORIN S.P.A. ("SORIN"), CYBERONICS, HOLDCO, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.

Investors and shareholders are able to obtain free copies of the definitive proxy statement/prospectus (once it becomes available) and other documents filed with the SEC by the parties through the website maintained by the SEC at In addition, investors and shareholders will be able to obtain free copies of the definitive proxy statement/prospectus and other documents filed with the SEC (1) on Cyberonics' website at within the "Investor Relations" section or by contacting Cyberonics' Investor Relations through its website at (for documents to be made available to Cyberonics shareholders) or (2) on Sorin's  website at (for documents to be made available to Sorin shareholders).

The release, publication or distribution of this press release in certain jurisdictions may be restricted by law, and therefore persons in such jurisdictions into which this communication is released, published or distributed should inform themselves about and observe such restrictions.

Italian CONSOB Regulation No. 11971 of May 14, 1999Prior to the extraordinary meeting of Sorin shareholders, Sorin has voluntarily made available an information document pursuant to Article 70, paragraph 6, of the CONSOB Regulation on Issuers (CONSOB Regulation no. 11971 of May 14, 1999, as amended), in accordance with applicable terms.

Italian CONSOB Regulation No. 17221 of March 10, 2010Pursuant to Article 6 of the CONSOB Regulation no. 17221 of March 12, 2010 (as amended, the "CONSOB Regulation"), HoldCo is a related party of Sorin, being a wholly owned subsidiary of Sorin. The merger agreement providing for the terms and conditions of the transaction, which exceeds the thresholds for "significant transactions" pursuant to the Regulation, was approved unanimously by the  board of directors of Sorin. The merger agreement and the merger of Sorin into HoldCo are subject to the exemption set forth in Article 14 of the CONSOB Regulation and Article [13.1.(v)] of the "Procedura per operazioni con parti correlate" ("Procedures for transactions with related parties") adopted by Sorin on October 26, 2010 and published on its website ( Pursuant to this exemption, Sorin has not and will not publish an information document (documento informativo) for related party transactions as provided by Article 5 of the CONSOB Regulation.

Participants in the DistributionSorin, Cyberonics and HoldCo and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Cyberonics with respect to the proposed transactions contemplated by the proxy statement/prospectus. Information regarding the persons who are, under the rules of the SEC, participants in the solicitation of proxies from the shareholders of Cyberonics in connection with the proposed transactions, including a description of their direct or indirect interests, on account of security holdings or otherwise, will be set forth in the definitive proxy statement/prospectus filed with the SEC. Information regarding Cyberonics's directors and executive officers is contained in Cyberonics's Annual Report on Form 10-K for the year ended on April 25, 2014  and its Proxy Statement on Schedule 14A, dated July 30, 2014, which are filed with the SEC and can be obtained free of charge from the sources indicated above.

Cautionary Statement Regarding Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 27A of the Securities Act) concerning Cyberonics, Sorin, HoldCo, the proposed transactions and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise. They are based on current beliefs of the management of Cyberonics, Sorin, and HoldCo as well as assumptions made by, and information currently available to, such management, and therefore, you are cautioned not to place undue reliance on them. These forward-looking statements are subject to various risks and uncertainties, many of which are outside the parties' control. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. None of Cyberonics, Sorin or HoldCo undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.  Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the medical device industry, and other legal, regulatory and economic developments.  We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the applicable safe harbor provisions of the Exchange Act and the Securities Act described above. Factors that could cause actual results to differ materially from those in the forward-looking statements include the failure to obtain applicable regulatory or shareholder approvals in a timely manner or otherwise, or the requirement to accept conditions that could reduce the anticipated benefits of the proposed transactions as a condition to obtaining regulatory approvals; the failure to satisfy other closing conditions to the proposed transactions; the length of time necessary to consummate the proposed transactions, which may be longer than anticipated for various reasons; risks that the new businesses will not be integrated successfully or that the combined companies will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer to realize than expected; the inability of Cyberonics, Sorin, and HoldCo to meet expectations regarding the timing, completion and accounting and tax treatments with respect to the proposed transactions; risks relating to unanticipated costs of integration, including operating costs, customer loss or business disruption being greater than expected; reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; unanticipated changes relating to competitive factors in the industries in which the companies operate; the ability to hire and retain key personnel; the potential impact of announcement or consummation of the proposed transactions on relationships with third parties, including customers, employees and competitors; the ability to attract new customers and retain existing customers in the manner anticipated; reliance on and integration of information technology systems; changes in legislation or governmental regulations affecting the companies; international, national or local economic, social or political conditions that could adversely affect the companies or their customers; conditions in the credit markets; risks to the industries in which Cyberonics and Sorin operate that are described in the "Risk Factors" section of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC by Cyberonics and HoldCo and the analogous section from Sorin's annual reports and other documents filed from time to time with the Italian financial market regulator (CONSOB) by Sorin; risks associated with assumptions the parties make in connection with the parties' critical accounting estimates and legal proceedings; the parties' international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the parties' businesses, including those described in Cyberonics's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the SEC by Cyberonics and HoldCo and those described in Sorin's annual reports, registration documents and other documents filed from time to time with CONSOB by Sorin. Nothing in this communication is intended, or is to be construed, as a profit forecast or to be interpreted to mean that earnings per Sorin share or Cyberonics share for the current or any future financial years or those of the combined group, will necessarily match or exceed the historical published earnings per Sorin share or Cyberonics share, as applicable. None of Cyberonics, Sorin and HoldCo gives any assurance (1) that any of Cyberonics, Sorin or HoldCo will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results.

Contacts:For Sorin:
InvestorsDemetrio MauroChief Financial Officer

Sorin Group

Tel: +39 02 69969 512

e-mail: investor.relations@sorin.comFrancesca RambaudiDirector, Investor Relations

Sorin Group

Tel: +39 02 69969716

e-mail: investor.relations@sorin.comMediaGabriele Mazzoletti Director, Corporate Communications

Sorin Group

Tel: +39 02 69 96 97 85

Mobile: +39 348 979 22 01

e-mail: corporate.communications@sorin.comEdward SimpkinsFinsbury (London)

Tel: +44 7958 421 519

e-mail: edward.simpkins@finsbury.comKal GoldbergFinsbury (New York)

Tel: +(1) 646-805-2000

e-mail: kal.goldberg@finsbury.comFor Cyberonics:
Greg Browne
Chief Financial Officer
Cyberonics, Inc.
Tel: +(1) 281-228-7262



MediaAndrew Cole/Chris KittredgeSard Verbinnen & Co (New York)

Tel: +(1) 212-687-8080

London: Conrad Harrington

Tel: +44 (0)20 3178 8914 



SOURCE Cyberonics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorin And Cyberonics Announce Designees To Board Of Directors Of Combined Company
2. Sorin And Cyberonics Announce Executive Leadership Team For The New Company Upon Close Of Merger
3. Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating
4. Cyberonics And Sorin Group To Merge, Creating A New Premier Global Medical Technology Company
5. Imricor Medical Systems Announces License Agreement with Sorin Group
6. Massage Chair Distributor Inada USA Now Sponsoring National Public Radio (NPR)
7. Cyberonics Reports Quarter And Annual Results
8. Cyberonics To Present At The Barclays Global Healthcare Conference
9. Cyberonics Reports Fiscal 2015 Third Quarter Results
10. Cyberonics To Report Fiscal Year 2015 Third Quarter Results And Host Webcast And Conference Call On February 26, 2015
11. Cyberonics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:12/6/2019)... Wis. (PRWEB) , ... December 06, 2019 , ... ... USP 800, targeted for implementation this month, Kenall is introducing the CSEDOIC luminaire ... tightly controlled. USP 800 now requires the unpacking of hazardous drugs (HDs) and ...
(Date:12/6/2019)... ... 2019 , ... The Multiple System Atrophy Coalition (MSA Coalition), ... initiative to kickstart MSA research collaborations. Multiple system atrophy is a rare ... million in new bequests earmarked for research and combined with ongoing grassroots fundraising ...
(Date:12/5/2019)... ... December 05, 2019 , ... LeadingBiotech ,?an exclusive ... announces key issues to be discussed at its East/West CEO conference ... in San Francisco. , Kicking off the week of the J.P. ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... December 06, 2019 , ... ... frequently, six students in Salt Lake Community College’s (SLCC) Emergency Medical ... Rodgers and Chelise Schaefer—were awarded the AT&T Public Safety Hero Scholarship to support ...
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... ... symposium for healthcare professionals in Baltimore, Maryland at the AES Annual Meeting. The ... learning objectives: , 1. Understand methods of quantitative sEMG analysis during ictal events;, ...
(Date:12/5/2019)... MATEO, Calif. (PRWEB) , ... December 05, 2019 , ... ... fall asleep over 25 million times this year using Bible-based bedtime stories. Listeners have ... refreshed minds. , According to the Center for Disease Control, one third of Americans ...
(Date:12/5/2019)... ... 05, 2019 , ... Today at M Health Fairview University of ... member who will to help them take medicine, relax during anxious moments, encourage ... Rocket, presented by NutriSource® is a golden retriever and the first and only ...
(Date:12/4/2019)... ... , ... Healthcare Real Estate Insights™ magazine has announced the ... recognizing excellence in the areas of healthcare real estate (HRE) development and executive ... the GlobeSt Healthcare Conference today in Scottsdale, Ariz. , The awards are presented ...
Breaking Medicine News(10 mins):